Every investor knows that the best time to buy stocks is when they are on sale. Sometimes the bargain prices last a long time, like in 2008/2009, and sometimes the sales are short-lived like the flash-crash, or when the Federal Reserve mentions the end of quantitative easing. Often, the buying opportunities are a surprise, a black-swan event occurs and the market drops. During these events, the fortunate investor has some cash available and he/she can move quickly to scoop up some bargains. However, there are times that an investor, looking ahead, can see some future events that may cause a temporary drop in the market. The wise investor, knowing these events are coming, will have a watch list of potential companies to buy and some cash ready to take advantage of the sale. Looking out through the end of the year, I see four events that could cause the market to drop. All four of these events could disrupt the market, but all four of these events will be relatively short-lived. Raise some cash and have your wish list ready, because the market could be in for a bumpy ride.
Top Services Companies To Own For 2015: Citigroup Inc.(C)
Citigroup, Inc., a global financial services company, provides consumers, corporations, governments, and institutions with a range of financial products and services. The company operates through two segments, Citicorp and Citi Holdings. The Citicorp segment operates as a global bank for businesses and consumers with two primary businesses, Regional Consumer Banking and Institutional Clients Group. The Regional Consumer Banking business provides traditional banking services, including retail banking, and branded cards in North America, Asia, Latin America, Europe, the Middle East, and Africa. The Institutional Clients Group business provides securities and banking services comprising investment banking and advisory services, lending, debt and equity sales and trading, institutional brokerage, foreign exchange, structured products, cash instruments and related derivatives, and private banking; and transaction services consisting of treasury and trade solutions, and securiti es and fund services. The Citi Holdings segment operates Brokerage and Asset Management, Local Consumer Lending, and Special Asset Pool businesses. The Brokerage and Asset Management Business, through its 49% stake in Morgan Stanley Smith Barney joint venture and Nikko Cordial Securities, offers retail brokerage and asset management services. The Local Consumer Lending business provides residential mortgage loans, retail partner card loans, personal loans, commercial real estate, and other consumer loans, as well as western European cards and retail banking services. The Special Asset Pool business is a portfolio of securities, loans, and other assets. Citigroup Inc. has approximately 200 million customer accounts and operates in approximately 160 countries. The company was founded in 1812 and is based in New York, New York.
Advisors' Opinion:- [By Jessica Alling]
Down the drain
JPMorgan, much like Bank of America (NYSE: BAC ) and Citigroup (NYSE: C ) , is finding itself with new problems associated with old business. While JPM hasn't had to step back into the courtroom like its rivals, it does have to settle some old scores. Because of its sale of derivatives to municipalities back in the day, JPMorgan may be facing up to $1.5 billion in losses. While this pales is comparison to the $8.3 billion case Citi is facing, and the potential $60 billion settlement that could swallow B of A whole, the number is no small change for the bank. - [By Rich Smith]
See that big green line of billion-dollar bills down there at the bottom? That's JPMorgan Chase's (NYSE: JPM ) deposit base -- and it's bigger than the next seven banks above it, combined -- including fellow 2B2Fers Citigroup (NYSE: C ) and Bank of America (NYSE: BAC ) .
- [By John Grgurich]
For�Citigroup� (NYSE: C ) , that person is CEO Michael Corbat. Here's the second of two articles taking an in-depth look at this relative newcomer to the superbank's top spot: where he came from, some of the important things he's said or done, and why you could arguably buy stock in the country's third-largest bank solely because of his ascendancy to CEO.
5 Best Stocks To Invest In 2014: Comverse Inc (CNSI)
Comverse, Inc. (CNS), incorporated on November 19, 1997, is a provider of software and systems enabling services for converged billing and active customer management, mobile Internet, and value-added services. The Company�� product portfolios includes value added services, billing and active customer management, and mobile Internet. The Company�� offerings include Comverse ONE, Comverse VAS, Comverse mobile Internet and Comverse global services.
The Company�� ONE deployment modes include Comverse ONE converged billing and active customer management, Comverse ONE real-time billing, Comverse ONE postpaid billing & active customer management, Comverse ONE online and converged charging, and create ONE of your own solutions. CNS is a wholly owned subsidiary of Comverse Technology, Inc.
Advisors' Opinion:- [By Lisa Levin]
Comverse (NASDAQ: CNSI) shares fell 2.50% to reach a new 52-week low of $25.75. Comverse's trailing-twelve-month profit margin is 2.86%.
Posted-In: 52-Week LowsNews Movers & Shakers Intraday Update Markets
5 Best Stocks To Invest In 2014: Perceptron Inc.(PRCP)
Perceptron, Inc. develops, produces, and sells non-contact measurement and inspection solutions in the Americas, Europe, and Asia. It offers AutoGauge systems that are used in the assembly and fabrication plants of automotive manufacturers; AutoGauge Plus, which offers freeform surface scanning and discrete feature measurement in one solution; AutoFit systems that are used in automotive manufacturing plants to contain, correct, and control the fit of exterior body panels; AutoScan systems, which provide a non-contact method of gathering data for the analysis of the surface contour of a part or product; and AutoGuide systems to calculate the difference between theoretical and actual relationships of a robot and the part being assembled, and send compensation data in six degrees of freedom to the robot. The company also offers ScanWorks, a hardware/software component set that allows customers to add digitizing capabilities to their machines or systems; ScanWorks xyz, a 3D sc anning solution designed for retrofitting 3-axis machines; ToolKit, a software solution for CMM manufacturers, system integrators, and application software developers; WheelWorks software and sensors that offer a non-contact method of measuring wheel position for use in automated or manual wheel alignment machines in automotive assembly plants; and Multi-line Sensors for use in automotive assembly plant wheel alignment systems. In addition, it manufactures visual inspection devices and accessories for the mechanical market; plumbing diagnostic equipment, meter imager systems, line detector accessories, and handheld inspection devices for the plumbing market; optical inspection devices for the construction and DIY market; and imaging solutions for the electrical market, as well as offers value-added services, including training, field services, launch support, consulting, maintenance agreements, repairs, and software tools. The company was founded in 1981 and is headquartered in Plymouth, Michigan.
Advisors' Opinion:- [By Garrett Cook]
In trading on Tuesday, industrials shares were relative leaders, up on the day by about 0.26 percent. Top gainers in the sector included Perceptron (NASDAQ: PRCP), up 10.9 percent, China Ming Yang Wind Power Group (NYSE: MY), up 4.8 percent.
5 Best Stocks To Invest In 2014: EnteroMedics Inc.(ETRM)
EnteroMedics Inc., a clinical development stage medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity and associated co-morbidities, and other gastrointestinal disorders. The company?s proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. Its product under development is the Maestro System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. The company intends to market its products to potential referral source clinicians, including general practitioners, internists, endocrinologists, and nurses. It has collaboration agreement with Mayo Clinic and Australian Institute of Weight Control. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003 . EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.
Advisors' Opinion:- [By John Udovich]
On Tuesday, small cap EnteroMedics Inc (NASDAQ: ETRM) soared 63.5% after reporting new clinical trial data for its Maestro system that is designed to control obesity, meaning it might be time to take a closer look at the stock along with the performance of other small cap obesity drug or treatment players like Arena Pharmaceuticals, Inc (NASDAQ: ARNA), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS).
- [By Roberto Pedone]
One under-$10 health care player that's starting to trend within range of triggering a big breakout trade is EnteroMedics (ETRM), which is engaged in design and development of devices that use neuroblocking technology to treat obesity, its associated co-morbidities and other gastrointestinal disorders. This stock has been hit hard by the sellers so far in 2013, with shares off sharply by 59%.
If you take a look at the chart for EnteroMedics, you'll notice that this stock recently formed a double bottom chart pattern $1 to $1.01 a share. Following that bottom, shares of ETRM have started to rip higher and trend back above its 50-day moving average at $1.08 a share with strong upside volume flows. This move is quickly pushing ETRM within range of triggering a big near-term breakout trade.
Traders should now look for long-biased trades in ETRM if it manages to break out above some near-term overhead resistances levels at $1.14 to $1.19 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 584,986 shares. If that breakout triggers soon, then ETRM will set up to re-test or possibly take out its next major overhead resistance levels at $1.37 to $1.47 a share. Any high-volume move above those levels will then give ETRM a chance to re-fill some of its previous gap down zone from February that started above $3 a share.
Traders can look to buy ETRM off weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of $1.08 a share, or below more key near-term support at $1 a share. One can also buy ETRM off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By John Udovich]
Small cap biotech Arena Pharmaceuticals, Inc (NASDAQ: ARNA) soared yesterday and last Friday on earnings as well as news that the company will expand its marketing and supply agreement with Japan based Eisai for its BELVIQ (lorcaserin HCl) obesity drug, meaning it might be time to take a closer look at other biotech stocks like Orexigen Therapeutics, Inc (NASDAQ: OREX), EnteroMedics Inc (NASDAQ: ETRM) and VIVUS, Inc (NASDAQ: VVUS) that are in the business of treating obesity. Specifically, Arena Pharmaceuticals announced an expanded agreement providing Eisai with exclusive commercialization rights for all countries worldwide (except for South Korea, Taiwan, Australia, Israel and New Zealand) for BELVIQ where Arena will receive an upfront payment of $60 million and is eligible to receive up to a total of $176.5 million in regulatory and development milestone payments - an increase of $123 million from the amount remaining available under the previous agreement. BELVIQ was approved in June 2012, but didn't reach the market until June 2013 due to logistical concerns like classification by the Drug Enforcement Administration. Its also�approved for use in adults who are obese or who are overweight and who have at least one serious medical condition (e.g. diabetes or high cholesterol).
- [By James E. Brumley]
Look out VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). There's a new weight-loss player ready to take aim at your target market, and its name is EnteroMedics Inc. (NASDAQ:ETRM). If the recent action from ETRM is any indication, the market thinks it could be a real threat to your weight-loss ventures.
No comments:
Post a Comment